Legal and Patent Activity PDL BioPharma actively engages in intellectual property management and litigation, as evidenced by their recent suit against Eli Lilly. This indicates a strong focus on protecting their technology assets, which could present opportunities for legal, consulting, or IP-related service providers.

Portfolio Divestments The company's recent sale of assets to LENSAR and Stanley Capital highlights a strategic focus on refining their portfolio and leveraging partnerships. Opportunities may exist to offer services related to M&A advisory, asset management, or strategic consulting.

Research & Development Focus With their involvement in biotechnology research and investments in companies like LENSAR and Noden Pharma, PDL BioPharma demonstrates ongoing innovation in medical technology and pharmaceuticals. This offers potential for technology vendors, lab equipment suppliers, and R&D service providers.

Financial Profile Generating substantial revenue in the range of $250 million to $500 million, PDL BioPharma presents opportunities for financial services, investment analysis, and corporate banking partnerships to support their growth and operational needs.

Industry and Market Position As a biotechnology research firm with a focus on therapy development and licensing, PDL BioPharma's competitive ecosystem includes biotech and pharmaceutical companies. This creates prospects for partnering with biotech service providers, technology licensing agencies, and collaborative research organizations.